You Position: Home > Paper
倍扎罗汀及其在皮肤科的应用
( views:152, downloads:9 )
- Author:
- No author available
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1673-4173.2005.04.002
- Key Word:
- 倍扎罗汀;RXR;皮肤疾病
Abstract： 倍扎罗汀是一种合成的维A酸X受体激动剂,与维A酸X受体高度特异性结合,主要通过影响与维A酸X受体形成异二聚体的多种细胞核受体发挥调节细胞生长、增殖与分化的作用.近年来,随着系统和局部应用适应证的不断扩大,其作用机制的研究也日益深入.
- [1]Jürgen V, Smit,Elke M G J, de Jong,Candida A E M, van Hooijdonk,etc.Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.[J].2004,51(2).
- [2]Peter Heald,Marilyn Mehlmauer,Ann G Martin,etc.Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial[J].2003,49(5).
- [3]V R, Agarwal,E D, Bischoff,T, Hermann,etc.Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).[J].2000,60.
- [4]Chunlei Zhang,Madeleine Duvic.Retinoids: therapeutic applications and mechanisms of action in cutaneous T‐cell lymphoma[J].2003,16(4).
- [5]Rakhshandra Talpur,Staci Ward,Narin Apisarnthanarax,etc.Optimizing bexarotene therapy for cutaneous T-cell lymphoma[J].2002,47(5).
- [6]Gullu, Gorgun,Francine, Foss.Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.[J].2002,100.
- [7]Michael Shapiro,Alain H. Rook,Michael S. Lehrer,etc.Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma[J].2002,47(6).
- [8]Li D,Li T,Wang F,etc.Functional Evidence for Retinoid X Receptor (RXR) as a Nonsilent Partner in the Thyroid Hormone Receptor/RXR Heterodimer.[J].2002,22(16).
- [9]Karen S McGinnis,Jacqueline M Junkins-Hopkins,Glen Crawford,etc.Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms[J].2004,50(3).
- [10]J I, Song,M N, Lango,J D, Hwang,etc.Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.[J].2001,61.
- [11]J.M. Hanifin,V. Stevens,P. Sheth,etc.Novel treatment of chronic severe hand dermatitis with bexarotene gel[J].2004,150(3).
- [12]Jürgen V Smit,Manon E.J Franssen,Elke M.G.J de Jong,etc.A phase II multicenter clinical trial of systemic bexarotene in psoriasis[J].2004,51(2).
- [13]Karen S, McGinnis,Michael, Shapiro,Carmela C, Vittorio,etc.Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.[J].2003,139.
- [14]Mukherjee R.,Strasser J.,Jow L.,etc.RXR Agonists Activate PPAR\u00a0-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo[J].1998.
- [15]Zhao Y,Qin S,Atangan LI,etc.Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis.[J].2004,279(29).
- [16]Whaley K,Duvic M,Nowlakha P,etc.Central hypothyroidism associated with retinoid X receptor-selective ligands.[J].1999,340(14).
- [17]Sha,Liu.Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.[J].2002,143.
- [18]M.E.J. Franssen,J.V. Smit,P.E.J. Van Erp,etc.A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion[J].2003,149(3).